All Products

CJC-1295 (with DAC) is a synthetic growth hormone–releasing hormone (GHRH) analog referenced in preclinical research literature for its receptor-binding characteristics and defined peptide structure. The Drug Affinity Complex (DAC) modification extends peptide stability through albumin-binding characteristics, allowing for prolonged activity in controlled laboratory investigations. It is supplied as a precisely characterized peptide compound for controlled laboratory investigation.

Oxytocin is a synthetic nonapeptide analog corresponding to a defined endogenous peptide sequence and is widely referenced in preclinical research literature for its receptor-binding characteristics and structural stability. It is supplied as a precisely sequenced peptide for controlled laboratory investigation.

DSIP is a synthetic nonapeptide analog referenced in preclinical research literature for its defined structural characteristics and short-chain peptide configuration. It is supplied as a precisely sequenced peptide for controlled laboratory investigation.

Thymalin is a synthetic thymic peptide analog referenced in preclinical research literature for its defined structural characteristics and zinc-dependent configuration. It is supplied as a short-chain peptide sequence for controlled laboratory investigation.

PE-22-28 is a synthetic short-chain peptide analog referenced in preclinical research literature for its defined structural characteristics and receptor interaction profile. It is supplied as a precisely sequenced peptide for controlled laboratory investigation.

CJC-1295 + Ipamorelin Blend is a dual-peptide research combination consisting of two structurally defined synthetic peptide sequences supplied together in a single vial. This blend is referenced in preclinical research contexts where combined peptide models are investigated under controlled laboratory conditions.

BPC-157 + TB-500 is a dual-peptide research combination consisting of two structurally defined synthetic peptide sequences supplied together in a single vial. This blend is referenced in preclinical research contexts where combined peptide models are investigated under controlled laboratory conditions.

Tesamorelin + Ipamorelin Blend is a dual-peptide research combination consisting of two structurally defined synthetic peptide sequences supplied together in a single vial. This blend is referenced in preclinical research contexts where combined peptide models are investigated under controlled laboratory conditions.

CJC-1295 + Ipamorelin Blend is a dual-peptide research combination consisting of two structurally defined synthetic peptide sequences supplied together in a single vial. This blend is referenced in preclinical research contexts where combined peptide models are investigated under controlled laboratory conditions.

BLEND Semax 9mg + Selank 6mg -15mg is referenced in scientific literature for investigations involving multi-peptide signaling interactions and receptor-associated pathway activity within controlled laboratory settings. Research evaluations commonly assess molecular stability, interaction characteristics, and signaling behavior in preclinical research models.

CJC-1295 No DAC 10mg is referenced in scientific literature for investigations involving peptide signaling interactions and receptor-associated pathway activity within controlled laboratory settings. Research evaluations commonly assess molecular stability, interaction characteristics, and signaling behavior in preclinical research models.

GLP1-SMA is a synthetic GLP-1 receptor agonist analog engineered for enhanced stability and extended biological half-life. It is widely referenced in preclinical research literature for its receptor-binding characteristics and structural modifications that improve resistance to enzymatic degradation. It is supplied as a precisely characterized peptide compound for controlled laboratory investigation.